Increased Sensitivity of Gastric Acid Secretion to Gastrin in Cirrhotic Patients with Portacaval Shunt

H. Jürgen Lenz, Thomas Struck, Heiner Greten, Michael A. Kiss, Viktor E. Eysselein, John H. Walsh, and Jon I. Isenberg
Medizinische Kernklinik und Poliklinik, Universität Eppendorf, Universität Hamburg, Hamburg, Federal Republic of Germany; Divisions of Gastroenterology, Departments of Medicine, University of California, San Diego Medical Center, San Diego, California 92103; Veterans Administration Medical Center, San Diego, California 92161; and Center for Ulcer Research and Education, Veterans Administration Medical Center Wadsworth, Los Angeles, California 90073

Abstract

We studied acid secretory responses to exogenous pentagastrin and to endogenous gastrin in 12 stable cirrhotic subjects with portacaval shunt, 12 unshunted cirrhotics, and 12 normal subjects. Basal and stimulated serum gastrin concentrations as well as basal and maximum acid outputs were similar in the three groups. At low doses of either exogenous pentagastrin or gastrin-17 (G17), cirrhotics with portacaval shunt secreted significantly greater amounts of gastric acid than unshunted subjects. After low doses of intragastric peptone, cirrhotics with portacaval shunt secreted significantly more acid than unshunted cirrhotics and normal subjects. At each measured serum gastrin concentration after either exogenous G17 or intragastric peptone meals, cirrhotics with portacaval shunt secreted more acid than the unshunted control groups and their dose-response curve was significantly shifted to the left. Thus, cirrhotic patients with portacaval shunt, gastric acid secretion is abnormally sensitive to both exogenously administered or endogenously released gastrin.

Introduction

The major life-threatening complication of cirrhosis of the liver is upper gastrointestinal bleeding due to esophageal bleeding or peptic ulcer (1). In order to prevent recurrent bleeding from esophageal varices, various types of surgical procedures to decompress the portal circulation have been utilized; the most common of these is the portacaval shunt (2). After portacaval shunt in dog, gastric acid secretion increased both in the basal state and in response to enteral and parenteral stimulants (3–5). The effects of portacaval shunt on basal and maximal acid secretion in humans reveal conflicting observations; some report no change (6), and others an increase (7). Although acid secretion in the presence of intragastric meals has not been tested in cirrhotic subjects, jejunal distension with a meal or a balloon sig-

ificantly increased gastric acid secretion in those with a portacaval shunt (+PCS)1, while in normal subjects (N) or unshunted cirrhotics (−PCS) jejunal distension was without effect (6, 8). The mechanism responsible for altered secretory responses in humans after portacaval shunt is unknown.

During a series of experiments designed to examine the effects of nutrient and nonnutrient jejunal meals in +PCS and −PCS (8), we observed that gastric acid secretion in +PCS was much more sensitive to intravenous infusion of the COOH-terminal pentapeptide of gastrin, pentagastrin, than −PCS and N (9). Since gastrin fragments containing less than eight amino acids are preferentially inactivated during hepatic transit (10), the differences between +PCS and −PCS may have been secondary to higher blood levels of pentagastrin in the shunted group. Therefore, the purpose of this study was to determine whether +PCS were more sensitive to endogenously released gastrin or to an exogenous gastrin, which is not preferentially metabolized in the liver (10), compared with −PCS as well as N.

Methods

Subjects: 12 patients with histologically documented cirrhosis, nine males and three females, their mean age 59 yr (range: 45 to 72 yr), were studied. Portacaval shunt, nine side-to-side and three end-to-side, had been performed for bleeding of esophageal varices 6 mo to 6 yr earlier. Shunt patency was confirmed by angiography within the preceding 12 mo. Since the +PCS group contained two variables regarding their health status, cirrhosis of the liver and portacaval shunt, two additional groups served as controls. 12 stable −PCS, nine males and three females, their mean age 59 yr (range: 44 to 71 yr), were studied. In nine, the diagnosis of cirrhosis has been established by needle biopsy of the liver, in three by clinical findings including prior jaundice, ascites, endoscopic demonstration of esophageal varices, and other features of Laennec’s cirrhosis (11). The +PCS and −PCS had a past history of ethanol abuse. At the time of study, all were outpatients, free of jaundice, clinical evidence of ascites, encephalopathy, and in good health. Ethanol intake was denied and none showed any evidence of alcohol intake during the study period. 12 normal subjects, nine males and three females, their mean age 58 yr (range: 41 to 70 yr), were also studied. None of the 36 subjects had a history to suggest peptic ulcer disease, and none took any medication on a regular basis or within 48 h before the study. Biochemical parameters including serum bilirubin, albumin, total protein, alkaline phosphatase, and prothrombin time were similar in the three groups. Only the serum glutamic oxaloacetic transaminase was significantly (P < 0.05) elevated

1. Abbreviations used in this paper: EC50, plasma gastrin concentration, which results in one-half maximal acid secretion; ED50, dose that induces one-half maximal acid secretion; ED50, corrected for basal acid secretion; G17, human synthetic heptadecapeptide gastrin-17; N, normal subjects; +PCS, cirrhotic patients with portacaval shunt; −PCS, cirrhotic patients without portacaval shunt.
in cirrhosis compared with N: +PCs, 47±6 U/liter; −PCs, 51±8 U/liter; and N, 15±1 U/liter.

Experiments were approved by the Human Subjects Committee, University of California, San Diego on February 11, 1982 and by the Ethik Kommission, Universität Hamburg, on November 19, 1985. Written informed consent was obtained from each individual. Human synthetic heptadecapeptide gastrin-1 (G17) was given under investigational new drug No. 10,872 from the U.S. Food and Drug Administration, Washington, D.C.

Measurement of acid secretion in response to pentagastrin and G17. After a 12-h overnight fast, a double-lumen radiopaque nasogastric tube (model AN 10; H. W. Andersen Products Inc., Oyster Bay, NY) was fluoroscopically positioned with the tip in the gastric antrum. Residual gastric juice was aspirated for 15 min and discarded. Basal secretion was collected for two 15-min periods by continuous suction at −5 to −10 mmHg using a Stedman vacuum pump (model 2590 B; American Cytoscope Makers Inc., New York, NY). To maintain patency the tube was manually flushed with 10–20 ml of air and aspirated by hand at 5-min intervals. The volume of gastric juice was measured to the nearest milliliter. Hydrogen ion concentration was determined in vitro by automatic titration of a 0.2-ml aliquot with 0.2 M NaOH to pH 7.0 (Radiometer, Copenhagen, Denmark) (12).

After collecting basal secretions for 30 min, gastric acid secretion was measured in response to either graded doses of pentagastrin (Pep-tavlon; Ayerst Laboratories, New York, NY) or to graded doses of synthetic human gastrin 17-1 (G17) (Research Plus Inc., Bayonne, NJ). On one day, graded doses of pentagastrin (23.4, 93.8, 375, 1,500, and 6,000 ng/kg per h), and on another day, graded doses of G17 (2.34, 9.38, 37.4, 150, and 600 pmol/kg per h) were intravenously infused for 30 min by an infusion pump (model 975; Harvard Instrument Co., Inc., Millis, MA) in a stepwise fashion. Previous experiments indicated that gastric acid secretion did not significantly differ whether the doses of pentagastrin or of G17 were given sequentially on a single day or individually on separate days (13, 14).

Measurement of acid secretion in response to peptone. On a separate day and after measuring basal secretion for 30 min, liquid test meals, 500 ml each, containing peptone (Bacto-Peptone; Difco Laboratories, Detroit, MI) were given in increasing order of concentration (0.5, 1, 2.0, 4.0, and 8.0% wt/vol) adjusted to 310 mosmol/kg and pH 7.0 by the addition of NaCl and 4 m HCl, respectively. To control for the effect of distension alone, the zero dose contained 0.15 M NaCl adjusted to pH 7.0. The meal was instilled in the stomach through the nasogastric tube by gravity over 3 min. Gastric acid secretion was measured for 30 min by in vivo automatic intragastric titration at pH 7.0 by the addition of 0.5 M NaOH (15). 30 min after the instillation of each meal, the gastric contents were completely aspirated, the recovered volumes measured to the nearest milliliter, the stomach lavaged with 100 ml of 0.15 M NaCl, and the next meal instilled. Earlier studies indicated that intragastric administration of 8% peptone resulted in greater secretory response and that the secretory responses to each dose were not significantly altered when the titration time of 30 min was extended to 45 min (14). Furthermore, the acid secretory responses did not differ significantly whether the test meals were given sequentially on a single day or individually in random order on separate days (14).

Measurement of serum gastrin. Serum gastrin was measured in response to both intravenous infusion of G17 and the intragastric peptone meals. Venous blood was obtained at 30-min intervals through an indwelling intravenous plastic catheter (Abbocath-T 20 gauge; Abbott Laboratories, Inc., North Chicago, IL). The blood was allowed to clot for 30 min, centrifuged at 4°C, and sera were stored at −20°C for radioimmunoassay. Sera were measured in duplicate and the averages used. The antibody, 1611, was raised in rabbits immunized with G17 conjugated to bovine serum albumin (16). It was used in a final concentration of 1:250,000. This antibody is highly specific for both forms of gastrin (G17 and G34) and has <3% cross-reactivity with porcine cholecystokinin (16). With this antiserum, human G17 and human big gastrin (G34) were measured on a nearly equimolar basis (17).

Statistical analysis. Differences between treatment groups were determined by analysis of variance and the Newman-Keuls multiple range test (18). Differences were considered significant if P < 0.05. Results are expressed as means±SE. To calculate the dose that results in one-half maximal acid secretion dose (ED50) for pentagastrin and G17 dose-response studies, linear regression analysis was performed according to the following equation: response = calculated maximal response − ED50 (response/dose). ED50 is the negative slope of the equation. Since high basal values can give falsely low estimates of ED50 in dose-response studies, the basal-corrected ED50 (ED50c) was determined according to the following equation: ED50c = ED50 [1 − (B/M)], where B is basal rate of secretion and M is calculated maximal response + B (13, 19). To estimate the plasma gastrin concentration that resulted in one-half maximal gastric acid secretion (EC50), the individual gastric secretory responses after each dose of G17 or peptone were plotted against the corresponding plasma gastrin concentration. The EC50 were derived from the individual curves.

Results

Effect of pentagastrin. Basal acid outputs were 2.5±0.7 mmol/0.5 h in +PCs, 1.6±0.3 mmol/0.5 h in −PCs, and 1.8±0.3 mmol/0.5 h in N. These differences were not significant. Maximal acid outputs were similar in the three groups (Fig. 1). In response to low doses of pentagastrin, acid secretion was significantly (P < 0.01) greater in +PCs compared with the two unshunted control groups. The secretory rates in response to each dose of pentagastrin were similar in −PCs and N (Fig. 1). The mean dose of pentagastrin that was required to elicit one-half maximal gastric secretory responses was significantly lower in +PCs compared with both the −PCs and N; regardless of whether the absolute or the basal-corrected values for gastric acid secretion were examined (Table I). No significant differences of the pentagastrin ED50 were observed between −PCs and N.

Effect of G17. Basal acid outputs were not significantly (P

### Table 1. Mean (+ SE) Doses of Pentagastrin (ng·kg⁻¹·h⁻¹) to Elicit One-half Maximal Gastric Secretory Responses (ED50)

<table>
<thead>
<tr>
<th>Group</th>
<th>+PCs</th>
<th>−PCs</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED50c</td>
<td>52.5±6.4</td>
<td>133.9±25.5</td>
<td>150.6±22.9</td>
</tr>
<tr>
<td>ED50c</td>
<td>44.6±5.6</td>
<td>121.4±23.6</td>
<td>138.6±22.1</td>
</tr>
</tbody>
</table>

The subscript “c” in ED50 indicates that the individual data were corrected for basal acid secretion (13, 19). +PCs, 12 +PCs; −PCs, 12 −PCs; and N, 12 normal patients.

* P < 0.05 compared with +PCs.

† P < 0.01 compared with +PCs.
Figure 2. Gastric secretory rates and serum gastrin concentrations (inset) at basal (B) and in response to graded doses of human gastrin 17-1 (G17) in +PCS, −PCS, and N. **, P < 0.01 compared with −PCS and N.

> 0.1) different in +PCS (2.2±0.4), −PCS (1.6±0.4), and N (1.5±0.4 mmol/0.5 h) (Fig. 2). The maximal acid outputs to G17 were almost identical in N and −PCS, and were similar compared with the mean maximum acid output in the +PCS (Fig. 2). Gastric acid secretion in response to the three lowest doses of G17 was significantly (P < 0.01) greater in the +PCS group compared with the two −PCS groups (Fig. 2).

Serum gastrin concentrations at basal and during intravenous infusion of G17 were similar in +PCS, −PCS, and N (Fig. 2, inset). When the acid secretory responses were expressed in terms of the circulating serum gastrin concentrations (Fig. 3), the dose-response curve in the +PCS group was significantly shifted to the left. The plasma gastrin concentration following G17 that resulted in one-half maximal gastric acid secretion (EC50-G17) was 19.5±2.3 pmol in +PCS and significantly (P < 0.01) lower than the EC50-G17 in −PCS (60.9±7.5 pmol) and in N (68.4±8.1 pmol).

The dose of exogenous G17 required for one-half maximal acid secretory responses (ED50) was 7.7±0.6 in +PCS, 28.3±2.8 in −PCS, and 30.6±4.2 pmol/kg per h in the normal subjects (P < 0.01) (Fig. 4). Since basal secretion was numerically greater in those with portacaval shunt compared with those without portacaval shunt, the results were analyzed after subtracting basal acid outputs from the secretory responses to G17 in each individual subject. The mean ED50 corrected for basal (ED50c) remained significantly (P < 0.01) different between +PCS (6.4±0.5) compared with −PCS (26.3±3.0) and N (29.3±4.4 pmol/kg per h) (Fig. 4 B).

Effect of peptone meals. On the meal test days, basal acid secretion was similar in cirrhotics with portacaval shunt compared with −PCS and N, 2.3±0.2, 1.5±0.2, and 1.7±0.3 mmol/0.5 h, respectively. Maximum acid outputs in response
to peptone were almost identical in the three groups (Fig. 5). After instillation of 0.15 M NaCl alone, as a control for distension, gastric acid secretion was comparable in the three groups (Fig. 5). However, as observed with exogenous G17 infusions, the dose-response curve to peptone was also significantly \((P < 0.01)\) shifted to the left in those with portacaval shunt. For example, the lowest dose of peptone (0.5%) increased acid secretion to 58% of the maximal response in +PCS5 compared with 30% in −PC5 and 28% in N (Fig. 5).

Serum gastrin concentrations before and after 0, 0.5, 1.0, and 2.0% peptone were similar in the three groups (Fig. 5, inset). The gastrin responses to 4.0 and 8.0% peptone were numerically, yet not significantly \((P > 0.5)\), greater in the two unshunted control groups compared with +PC5.

When the individual serum gastrin concentrations after the test meals were related to the individual acid outputs, the curve of the +PC5 was significantly shifted to the left (Fig. 6). For example, a serum gastrin concentration of 35 pM was associated with a near maximum secretory response to the meal in the +PC5, while in both the −PC5 and N the secretory response was 58% of maximum. The test meal that contained 0.15 M NaCl (0% peptone) produced serum gastrin concentrations and acid secretory rates that were similar in the three groups (Fig. 6, the lowest values in each group). However, at each gastrin concentration after the peptone meals, +PC5 secreted more acid than either of the two unshunted groups (Fig. 6). The plasma gastrin concentration after the peptone meals that resulted in one-half maximal acid secretion (ED50-peptone) was 22.8 ± 1.8 pM in +PC5 and significantly \((P < 0.01)\) lower than the ED50-peptone in the −PC5 (31.7 ± 2.6 pM) and in N (34.9 ± 2.6 pM).

**Discussion**

The results of this study indicate that (a) Basal gastric acid secretion was slightly, yet not significantly, greater in +PC5 compared with −PC5 and N; (b) Maximal acid secretion in response to either pentagastrin, human gastrin 17-I (G17), or protein meals was similar in +PC5, −PC5, and N; (c) Gastric acid secretion was significantly more sensitive to exogenously administered pentagastrin or G17, as well as to endogenously released gastrin in +PC5, compared with −PC5 and N.

Maximal acid output in response to histamine was increased in dog after portacaval anastomosis (5). Prior studies in humans using histamine as the gastric agonist (6), and the present study, indicate that maximal acid output either in response to pentagastrin or G17 was similar in +PC5 compared with −PC5 and N. These observations indicate that the total parietal cell mass is not increased in humans after portacaval shunt (12).

Acid secretion in response to an intragastric meal was increased in dogs with separated gastric (Dr. Heidenhain) pouches after portacaval transposition (5), but has not previously been studied in humans. Our results demonstrate that acid output in response to a maximally stimulating dose of an intragastric peptone meal (14) was similar in +PC5, −PC5, and in N.

At pharmacologic serum gastrin concentrations, gastric acid secretion was similar in the shunted and unshunted subjects, while at physiological serum gastrin concentrations of 50 pM and less (20), gastric acid secretion was significantly more sensitive to circulating gastrins in patients with portacaval shunt. It appears that the parietal cell in cirrhotic patients after portacaval shunt is exceedingly sensitive to gastrin. Increased sensitivity of the gastric mucosa to human gastrin has also been reported in the rat after portacaval shunt (21).

In +PC5, but not in −PC5 or N, jejunal distension with a balloon or a hyperosmolar solution resulted in significant secretory responses (6, 8). It has been suggested that a humoral substance may be released from the small intestine that enhances gastric acid secretion when it bypasses the liver (22). The partial isolation of a nongastrin agonist of gastric acid secretion from the porcine small intestine referred to as the intestinal phase hormone or entero-oxytint has been described (22, 23). It is possible that such a humoral agent, secreted by the human proximal small intestine and normally inactivated by the liver, functions as an agonist of acid secretion after portacaval shunt. This would explain the observation that in +PC5, the administration of low doses of peptone meals, that did not alter serum gastrin concentrations, resulted in significant increases in gastric acid secretion. Also, since stimulants of acid secretion, such as histamine and gastrin, resulted in a potentiated response when administered in combination (24), it is possible that an intestinal stimulant contributed to the increased sensitivity to intravenous pentagastrin and G17, as well as to the peptone meals.

Portacaval shunt diverts mesenteric blood directly into the systemic circulation, bypassing the liver, which is one of many sites involved in gastrin metabolism (25). Therefore, higher levels of gastrin in the +PC5 could have mimicked the observed increased sensitivity. However, circulating gastrin levels were similar during intravenous infusion of G17 in those with and those without portacaval shunt. Also, gastrin fragments containing less than eight amino acids are preferentially removed by hepatic transit (10). Therefore, small circulating forms of gastrin not measurable by radioimmunoassay could result in the observed increased sensitivity to G17 and the peptone meals, as well as account for the slightly elevated basal secretion. If increased concentrations of small circulating gastrin fragments at basal were to cause the increased sensitivity to G17, the additive effect of those molecular forms together with exogenous G17 could mimic the increased sensitivity. After subtracting the basal values, which, in part, may be due to small and large circulating forms of gastrin molecules, +PC5 were still more sensitive than the unshunted control groups. This suggests that increased concentrations of small gastrin fragments did not contribute to the hypersensitivity of +PC5 that was observed in response to exogenous G17. However, it is possible that peptone meals induced the release of small molecular forms of gastrin that were not detected by the radioimmunoassay. These gastrin fragments that are not removed by hepatic transit (10) could contribute to the increased sensitivity of gastric acid secretion to peptone meals in the +PC5.

---

**Figure 6.** Comparison of the relationship between gastric acid secretion and serum gastrin concentrations after increasing doses of intragastric peptone meals in +PC5, −PC5, and N.

---

*Increased Sensitivity to Gastrin in Shunted Cirrhotics* 1123
In summary, the results of this study indicate that gastric acid secretion is very sensitive to exogenously administered and endogenously released gastrin in +PCS, compared to −PCS, and N. Increased sensitivity to gastrin may be due to the presence of an intestinal agonist of acid secretion that is normally inactivated within the liver. Other factors that may be released by intragastric peptone (e.g., small gastrin fragments) may also contribute to the increased sensitivity of meal-stimulated gastric acid secretion in +PCS.

Acknowledgments

The authors thank Dr. Joseph Steinbach and Professor Rehpenning for statistical advice, Ms. Erika Friemel and Ms. Karin Feutlinke for technical assistance, Drs. Marshall J. Orloff and Richard Bell for referring some of the patients, and Ms. Nancy Hartung for preparation of the manuscript.

These studies were supported by the Deutsche Forschungsgemeinschaft (Le 470/1-2 and Le 470/2-1), the National Institutes of Arthritis, Metabolism and Digestive Disease (grants AM 17328 and AM 33491-02), and by the Veterans Administration.

References


